Last reviewed · How we verify
NCT04945681: EEPICC
Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People
Phase 4 trial testing Pneumococcal conjugate vaccine in Pneumococcal Infections in 2,882 participants. Participants enrolled and being followed up; not accepting new ones.
18 January 2025
Quick facts
| Lead sponsor | London School of Hygiene and Tropical Medicine |
|---|---|
| Phase | Phase 4 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 2,882 |
| Start date | 27 November 2022 |
| Primary completion | 18 January 2025 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across Somalia |
Drugs / interventions tested
- Pneumococcal conjugate vaccine — full drug profile →
Conditions studied
- Pneumococcal Infections — all drugs for Pneumococcal Infections →
Sponsor
London School of Hygiene and Tropical Medicine
Who can join
Adults 6 Weeks to 4, any sex, with Pneumococcal Infections. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pneumococcal conjugate vaccine (PCV) is used routinely worldwide as part of infant immunisations to prevent acquisition of S. pneumoniae, the aetiologic agent responsible for a large proportion of early childhood pneumonia and invasive disease. However, PCV has seen minimal uptake in populations affected by forced displacement and humanitarian crises, where the burden of pneumococcal disease is plausibly elevated. This study seeks to generate evidence on appropriate vaccination strategies for crisis-affected populations. The investigators plan to exhaustively vaccinate children aged between six months and four years in a camp for displaced persons outside Hargeisa, the capital of Somaliland. The study will deliver PCV in a campaign modality, so as to achieve both short- and long-term herd immunity effects that, the investigators hypothesise, will reduce population-wide nasopharyngeal S. pneumoniae transmission and thereby protect young children from pneumococcal disease. The study will adopt a quasi-experimental design, with baseline and post-intervention surveys to evaluate changes in pneumococcal carriage, complemented by safety assessment in children aged over 2 years, who fall outside of the WHO prequalification age range for the vaccine that will be used in this study (i.e. PNEUMOSIL) and for whom PCV safety data are scarce. In addition, we the study will also collect longitudinal data on incidence of pneumonia and antibiotic prescriptions in the camp.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Safety and coverage of Pneumosil pneumococcal polysaccharide conjugate vaccine (10-valent PCV) in a camp for internally displaced persons in Somaliland.
McGowan CR, van Zandvoort K, Ibrahim SA, Hassan AI, et al · · 2026 · PMID 41265006 · DOI 10.1016/j.vaccine.2025.127991
Verify or expand the search:
- PubMed search for NCT04945681
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pneumococcal conjugate vaccine
Trials testing the same drug.
- NCT03109600 — Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I) · Phase 1 · completed
Other recruiting trials for Pneumococcal Infections
Currently open trials in the same condition.
- NCT06822907 — Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults · Phase 4 · recruiting
- NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06608199 — A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 · Phase 3 · recruiting
- NCT04664556 — Invasive Pneumococcal Disease Study · recruiting
Other London School of Hygiene and Tropical Medicine trials
Trials by the same sponsor.
- NCT06921213 — Comprehensive Ambulatory Antibiotics for the Treatment of Congenital Syphilis · Phase 2 · not yet recruiting
- NCT06923592 — Serological Testing and Treatment for Plasmodium Vivax Malaria: a Trial in Ethiopia and Madagascar · Phase 3 · recruiting
- NCT06833736 — A Health App Using Recipes and Education Components to Facilitate Sustainable and Healthier Diets. · NA · completed
- NCT06166498 — Parasite Clearance and Protection From Infection (PCPI) in Zambia · Phase 3 · completed
- NCT06173206 — Parasite Clearance and Protection From Infection (PCPI) in Cameroon · Phase 3 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04945681 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by London School of Hygiene and Tropical Medicine
- Last refreshed: 4 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04945681.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing